Medifast Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Medifast şirketinin toplam hissedar öz sermayesi $207.3M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $291.2M ve $83.9M dir. Medifast 'in FAVÖK'ü $23.3M faiz karşılama oranı -4.6 dur. Şirketin $170.0M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	-4.6x
Nakit	US$169.96m
Eşitlik	US$207.34m
Toplam yükümlülükler	US$83.90m
Toplam varlıklar	US$291.24m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 0K05 'nin kısa vadeli varlıkları ( $225.0M ) kısa vadeli yükümlülüklerini ( $72.4M ) aşıyor.

Uzun Vadeli Yükümlülükler: 0K05 şirketinin kısa vadeli varlıkları ( $225.0M ) uzun vadeli yükümlülüklerini ( $11.5M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 0K05 borçsuzdur.

Borcun Azaltılması: 0K05 un 5 yıl önce borcu yoktu.

Borç Kapsamı: 0K05 un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: 0K05 şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

Medifast Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Third quarter 2024 earnings released: EPS: US$0.10 (vs US$2.12 in 3Q 2023)

Medifast, Inc. Provides Earnings Guidance for the Fourth Quarter of 2024

Medifast, Inc. to Report Q3, 2024 Results on Nov 04, 2024

New major risk - Revenue and earnings growth

New minor risk - Profit margin trend

Second quarter 2024 earnings released: US$0.75 loss per share (vs US$2.78 profit in 2Q 2023)

Medifast, Inc. to Report Q2, 2024 Results on Aug 05, 2024

Now 43% overvalued

Now 46% overvalued

Now 52% overvalued

Now 21% overvalued

Investor sentiment deteriorates as stock falls 15%

Investor sentiment deteriorates as stock falls 24%

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: EPS: US$0.76 (vs US$3.68 in 1Q 2023)

Now 22% overvalued

Medifast, Inc. Provides Earnings Guidance for the Second Quarter of 2024

Medifast, Inc. to Report Q1, 2024 Results on Apr 29, 2024

Investor sentiment deteriorates as stock falls 16%

Independent Director recently sold US$109k worth of stock

New major risk - Revenue and earnings growth

Full year 2023 earnings released: EPS: US$9.13 (vs US$12.82 in FY 2022)

Medifast Provides Earnings Guidance for the First Quarter of 2024

Medifast, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Investor sentiment deteriorates as stock falls 16%

New minor risk - Share price stability

Now 20% undervalued after recent price drop

Medifast, Inc. Provides Earnings Guidance for the Full Year 2023

New minor risk - Insider selling

Medifast, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Medifast, Inc. Announces Optavia Active Now Available

Medifast, Inc. Declares Quarterly Cash Dividend, Payable on November 7, 2023

Medifast, Inc. Provides Earnings Guidance for the Third Quarter 2023

Second quarter 2023 earnings released: EPS: US$2.78 (vs US$3.45 in 2Q 2022)

Medifast Unveils New Product Line, Optavia Active

Medifast, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Now 20% undervalued after recent price drop

Now 22% undervalued after recent price drop

Medifast, Inc. Declares Quarterly Cash Dividend, Payable on August 8, 2023

Medifast, Inc., Annual General Meeting, Jun 14, 2023

First quarter 2023 earnings released: EPS: US$3.68 (vs US$3.62 in 1Q 2022)

Now 26% undervalued after recent price drop

Full year 2022 earnings released: EPS: US$12.82 (vs US$14.01 in FY 2021)

Medifast, Inc. to Report Q4, 2022 Results on Feb 21, 2023

Upcoming dividend of US$1.64 per share

Medifast, Inc. Announces Quarterly Dividend, Payable on February 7, 2023

Insufficient new directors

Now 22% undervalued after recent price drop

Third quarter 2022 earnings released: EPS: US$3.30 (vs US$3.59 in 3Q 2021)

Medifast, Inc. Revises Earnings Guidance for the Year 2022

Medifast, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Upcoming dividend of US$1.64 per share

Medifast Announces Quarterly Dividend, Payable on November 8, 2022

Now 20% undervalued after recent price drop

Lead Independent Director recently bought US$499k worth of stock

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: EPS: US$3.45 (vs US$4.00 in 2Q 2021)

Medifast, Inc. Revises Earnings Guidance for the Full-Year of 2022

Medifast Announces New Scientific Advisory Board Appointments

Medifast, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Medifast, Inc.(NYSE:MED) dropped from Russell 2000 Dynamic Index

Upcoming dividend of US$1.64 per share

Medifast, Inc. Announces Quarterly Dividend, Payable on August 8, 2022

Executive Chairman & CEO recently bought US$79k worth of stock

First quarter 2022 earnings released

Medifast, Inc. Revises Earnings Guidance for the Full-Year of 2022

Insufficient new directors

Medifast, Inc., Annual General Meeting, Jun 15, 2022

Medifast, Inc. to Report Q1, 2022 Results on May 02, 2022

Insider recently sold US$200k worth of stock

Medifast, Inc. Provides Earnings Guidance for the Full-Year 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Medifast, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Upcoming dividend of US$1.42 per share

Insufficient new directors